Skip to main content
. Author manuscript; available in PMC: 2016 Jan 15.
Published in final edited form as: Clin Cancer Res. 2014 Nov 19;21(2):365–372. doi: 10.1158/1078-0432.CCR-14-1683

Figure 4.

Figure 4

Association of rs34231037 with changes in serum [sVEGFR2] after pazopanib therapy. Dot and boxplots demonstrate: (a) replication of the association between the SNP and baseline serum [sVEGFR2] among an independent cohort of 121 renal cancer patients, (b) the serum [sVEGFR2] measurements by genotype in the same 121 subjects after 4 weeks pazopanib therapy, and (c) the fractional change in serum [sVEGFR2] among these subjects by genotype.